Floatz logo

GADOLINIC ACID, (N-(2-(BIS((CARBOXY-.KAPPA.O)METHYL)AMINO-.KAPPA.N)-3-(4-ETHOXYPHENYL)PROPYL)-N-(2-(BIS((CARBOXY-.KAPPA.O)METHYL)AMINO-.KAPPA.N)ETHYL)GLYCINATO(5-)-.KAPPA.N,.KAPPA.O)-

Castration-resistant Prostate Cancer

University of CincinnatiSmall moleculeEarly Phase 1Dormant
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
81/ 100

Competitive context

31 Active assets in the Castration-resistant Prostate Cancer cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 4BBB
RADIUM RA-223
Bayer
Phase 4BB
Abiraterone Acetate
AstraZeneca
Phase 4BB
Zoladex
Bayer
Phase 3BB
Seviteronel
Innocrin Pharmaceutical
Phase 2BB

View all 50 →

Same molecule, other indications

GADOLINIC ACID, (N-(2-(BIS((CARBOXY-.KAPPA.O)METHYL)AMINO-.KAPPA.N)-3-(4-ETHOXYPHENYL)PROPYL)-N-(2-(BIS((CARBOXY-.KAPPA.O)METHYL)AMINO-.KAPPA.N)ETHYL)GLYCINATO(5-)-.KAPPA.N,.KAPPA.O)- is also rated in:

Carcinoma, HepatocellularDormant
BB
Indicative ·
65 / 100
View asset →
CirrhosisDormant
B
Indicative ·
62 / 100
View asset →
hepatocellular carcinomaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →